EUVIMEDEUVIMED entdecken
Open Access

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212 Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Kjetil Berner, Eivor Hernes, Monika Kvassheim, Mona-Elisabeth Revheim, Julie Bastiansen, Silje Selboe, Charlotte L Bakken, Simen R Grønningsæter, Øyvind S Bruland, Roy H Larsen, Lily Bouzelmat, Vicki L Jardine und 1 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.269299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Kjetil Berner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antigens, Surface, Glutamate Carboxypeptidase II, Lead Radioisotopes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntigens, SurfaceGlutamate Carboxypeptidase IILead RadioisotopesHumansMaleAgedNeoplasm MetastasisTissue DistributionMiddle AgedSingle Photon Emission Computed Tomography Computed TomographyLigandsRadiopharmaceuticals

Stichwörter der Autor:innen

212PbPSMAimagingmCRPCtargeted α-therapyα-radioligand therapy

Substanzen

Antigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, humanLead RadioisotopesLead-212LigandsRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
  • Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Intervention Centre, Oslo University Hospital, Oslo, Norway.
  • Department of Physics, University of Oslo, Oslo, Norway.

Zitieren

APA

Berner, K., Hernes, E., Kvassheim, M., Revheim, M. E., Bastiansen, J., Selboe, S., Bakken, C. L., Grønningsæter, S. R., Bruland, Ø. S., Larsen, R. H., Bouzelmat, L., Jardine, V. L., & Stokke, C. (2025). First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212 Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269299

Vancouver

Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, et al. First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212 Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269299

BibTeX
@article{Berner2025,
  author = {Berner, Kjetil and Hernes, Eivor and Kvassheim, Monika and Revheim, Mona-Elisabeth and Bastiansen, Julie and Selboe, Silje and Bakken, Charlotte L and Grønningsæter, Simen R and Bruland, Øyvind S and Larsen, Roy H and Bouzelmat, Lily and Jardine, Vicki L and Stokke, Caroline},
  title = {First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212 Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.269299}
}
Kostenlos starten →